GLOW

What is the GLOW peptide blend?

GLOW is the informal name for a three-peptide blend: GHK-Cu (copper complex of glycyl-L-histidyl-L-lysine), BPC-157 (synthetic 15-aa peptide), and TB-500 (generally N-acetylated thymosin beta-4 17–23, `Ac-LKKTETQ`).

It is promoted around a broad “repair plus appearance” concept. GLOW is not one new peptide—three separate compounds lyophilized in a single vial, each with its own molecular weight, mechanism, stability, pharmacokinetics, and evidence base.

Standard GLOW composition

The 70 mg formula is the dominant convention, but “GLOW” is a market name rather than a standardized formulation. Products with 35 mg, 42 mg, and other totals also exist, sometimes with different ratios. A unit chart is valid only for the vial composition printed above it.

Identity checks before comparing GLOW protocols

TB-500 versus full-length thymosin beta-4: Products sold as TB-500 have been identified as `Ac-LKKTETQ`. Some GLOW suppliers instead claim full-length TB4 while still using the TB-500 name—these should not share a dosage table.

GHK versus GHK-Cu: Confirm peptide identity and copper complexation, and whether stated mass refers to the complex, peptide alone, or separately added copper.

BPC-157 sequence and salt: Document free base vs acetate, peptide content, and whether stated mass includes salt, water, or excipient.

Current research and compounding status

GLOW itself has not been evaluated as a fixed combination. In July 2026, an FDA advisory committee narrowly recommended that BPC-157 and TB-500-related bulk substances be considered for the 503A compounding list. The votes were advisory and did not assess the GLOW ratio, dose, stability, or outcomes. GHK-Cu was not part of that meeting.

There is no US prescribing information establishing a GLOW dose.

Has the exact GLOW blend been studied?

No controlled human or animal dose-ranging study of the exact 50/10/10 GLOW blend was identified. The blend therefore cannot be described as synergistic in the clinical sense. Its rationale is a mechanistic hypothesis assembled from separate component studies.

Human research on the individual components

Topical GHK-Cu does not define systemic copper-peptide exposure. Full-length Tβ4 contains functional regions not present in the seven-residue fragment. Small BPC-157 reports used different routes, populations, and amounts. Combining those findings cannot reconstruct a trial of subcutaneous GLOW.

GLOW research dosage

Most modern GLOW protocols cluster around 2.3–3.5 mg of total blend per administration—driven by convenient dilutions and placing BPC-157 and TB-500 near 300–500 mcg each while delivering approximately 1.7–2.5 mg GHK-Cu.

Complete reported GLOW research protocol

The following four-week protocol is the simplest and most consistently repeated complete schedule. One standard vial supplies the nominal cycle. It assumes a 70 mg vial with 3 mL diluent (≈23.33 mg/mL); 10 units = 0.10 mL.

The standard protocol is fixed-dose after an optional lead-in. Some sources escalate 5 → 10 → 15 units, but no GLOW dose-response study supports automatic escalation.

Early-stop criteria (examples): severe/progressive injection-site reaction; allergic symptoms; persistent nausea, dizziness, headache, fatigue, or flushing; marked BP/HR change; infection signs; neurological symptoms; unexpected worsening of the target condition. Urgent symptoms require medical evaluation—not a dilution change.

Alternative 12-week fixed-dose frequency-taper protocol

This longer protocol keeps the amount per administration constant at 2.8 mg while reducing frequency. It assumes 2.5 mL diluent (28 mg/mL); 10 units delivers 2.8 mg. Nominal cycle totals 168 mg (≈2.4 vials → three 70 mg vials before handling loss). No study shows superiority over a shorter daily cycle.

Alternative loading and maintenance protocol

Another community pattern mirrors the KLOW loading approach. With 2 mL added to a 70 mg vial, 10 units = 3.5 mg and 5 units = 1.75 mg. Loading uses 70 mg in four weeks; maintenance uses 42 mg over eight weeks (112 mg total ≈ 1.6 vials). “Loading” is a community term—GLOW pharmacokinetics have not established a loading requirement.

GLOW reconstitution and concentration math

“10 units of GLOW” is not a reproducible dose without vial mass, component ratio, and diluent volume. Depending on dilution, 10 units delivers 2.33, 2.8, or 3.5 mg.

Reported GLOW dosage range

Anecdotal versus clinically studied dosing

Why the three peptides are combined

The marketing narrative assigns matrix remodeling, vascular support, and repair-cell migration. These pathways overlap, and all three may influence inflammation and angiogenesis. No experiment has shown that the 5:1:1 ratio optimizes the interaction.

Component evidence in more detail

1. GHK-Cu — extensive laboratory and topical research; mixed topical clinical results (diabetic ulcers vs CO₂-laser resurfacing). Supports a topical rationale, not systemic GLOW dosing.
2. BPC-157 — numerous rodent models; human evidence sparse and weak. A two-person IV pilot cannot define a chronic SC dose.
3. TB-500 — `LKKTETQ` actin-binding region promotes migration/repair in preclinical models. Full-length Tβ4 human studies evaluated a different molecule by IV or topical routes.

Dosage evidence ladder

Safety and adverse effects

No exact-combination adverse-event rate exists. GHK-Cu constitutes more than 70% of GLOW by mass—the copper contribution should not be ignored. Fixed-ratio convenience means reducing GHK-Cu also reduces BPC-157 and TB-500.

Storage and stability

Community guides usually specify 2–8°C after reconstitution, protection from light, gentle swirling, and use within approximately 28 days. No published stability study was identified for the complete GLOW mixture under these conditions.

A pale blue or blue-green appearance is expected from the copper complex. Color alone does not confirm concentration, sterility, or intact peptide. Cloudiness, unexpected particulate matter, or a marked color change is a product-quality warning.

Anti-doping status

BPC-157 and thymosin beta-4 derivatives are prohibited under the WADA framework. Because GLOW contains both, it is incompatible with tested sport.

Bottom line

GLOW is a fixed 5:1:1 blend. The dominant 70 mg formula contains 50 mg GHK-Cu and 10 mg of each repair peptide. The most repeated daily amount is approximately 2.33 mg total (≈1.67 mg GHK-Cu + 333 mcg each of BPC-157 and TB-500).

The simplest complete community protocol uses 2.33 mg once daily for four weeks, then a 2–4-week washout. Longer protocols keep 2.8 mg constant while reducing frequency across 12 weeks, or use a 3.5 mg loading phase followed by 1.75 mg maintenance.

Confirm true 50/10/10 ratio, fragment TB-500 vs full-length Tβ4, component-specific potency, verified copper complexation, sterility, endotoxin, and post-reconstitution stability — before trusting any unit chart.

Frequently asked questions

References

• FDA

  July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting

  Advisory votes — not a GLOW blend evaluation.

• FDA

  Bulk drug substances nominated for use in compounding

  Updated May 2026; GHK-Cu category distinctions.

• Pickart L, Margolina A.

  Regenerative and protective actions of GHK-Cu

  2018 review — topical/lab context.

• Mulder GD et al.

  Topical GHK-Cu in diabetic neuropathic ulcers

  1994 — not injectable GLOW dosing.

• Esposito S et al.

  Identification of acetylated thymosin beta-4 17–23 in TB-500

  2012.

• Ho ENM et al.

  TB-500 chemistry and detection

  2012.

• Morris DC et al.

  Thymosin beta-4 active sites and biological activity

  2010.

• BPC-157 IV pilot

  Safety of IV BPC-157 in two adults

  2025 — not SC blend validation.

• Sports medicine review

  Injectable peptide therapy in orthopaedic and sports medicine

  2025.

• WADA

  2026 Prohibited List

  BPC-157 and Tβ4 derivatives prohibited.